- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01223053
Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury
September 4, 2012 updated by: Imprimis Pharmaceuticals, Inc.
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Confirmatory Phase 3 Study to Assess the Efficacy and Safety of TDLP-110 (Ketotransdel®, Ketoprofen 10% Cream) in the Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury
Transdel Pharmaceuticals is investigating a topical cream formulation consisting of 10% ketoprofen for the local treatment of pain associated with mild to moderate acute soft tissue injury in this confirmatory Phase 3 trial.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This Phase 3 study examines the use of TDLP-110 (a.k.a.
Ketotransdel® or ketoprofen 10% cream), as a topical treatment for pain associated with mild to moderate acute soft tissue injury of the upper and lower extremities to serve as a confirmatory trial.
The first completed Phase 3 study showed efficacy and safety of TDLP-110 compared to placebo in improving the patient assessment of pain.
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Are male or female and 18 to 75 years of age, inclusive.
- Female patients of childbearing potential must practice abstinence or be using a medically acceptable form of contraception
- Have a diagnosis of uncomplicated acute soft tissue injury of the upper or lower extremity, including acute injuries of ligaments, tendons, or muscles (including Grade 1 or Grade 2 sprain or strain), that has occurred within the 60 hours preceding the baseline visit.
- Meet pain intensity criteria
- Are willing to discontinue use of any pain medication or treatments not provided as part of the study.
Exclusion Criteria:
- Participation in a previous clinical study with the drug TDLP-110 (ketoprofen 10% cream).
- Are pregnant or lactating.
- Have a Grade 3 sprain or strain, bilateral sprain or strain, or concomitant fracture or open wound at the site of the sprain or strain, or have a serious injury, as determined by the investigator
- Have a shoulder (rotator cuff) injury.
- Have been treated for a sprain or strain of the same site within the past 3 months.
- Have contusions at the site of acute soft tissue injury intended for treatment.
- Have active skin lesions or disease at the intended site of application of the study medication.
- Have had pharmacologic treatment for the injury less than 24 hours before the baseline assessments
- Use of any oral or parenteral corticosteroids within 30 days of injury.
- Have had non-pharmacologic treatments of the injury other than rest, ice, compression, and/or elevation (RICE) within 12 hours prior to the baseline visit.
- Have a history or physical examination finding that is incompatible with safe participation in the study.
- Have a history or physical examination finding that is, in the opinion of the investigator, incompatible with study product use or with obtaining interpretable data.
- Are taking medications or other substances contraindicated due to the nature of the study medication or with the potential for drug interactions.
- Are allergic or sensitive to soy lecithin or soy lecithin-containing products.
- Are taking probenecid or similar drugs that may significantly affect renal function.
- Are taking a sleep medication, sedative hypnotic, anxiolytic, or antidepressant medication at a dose that has not been stable for at least 2 months.
- Are receiving physical therapy for the index injury
- Have scheduled elective surgery or other invasive procedures during the period of study participation.
- Have any illness or concurrent condition that would, in the opinion of the investigator, make study participation unsafe or would confound study results ly undergoing treatment for chronic pain, or severe systemic disease).
- Have received an investigational drug or product or participated in an investigational drug study within a period of 30 days prior to receiving study medication.
- Have an active worker's compensation claim or personal injury claim regarding injury to the index site.
- Are suspected by the investigator of recent or current drug or alcohol abuse.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Cream
|
Matching placebo cream containing identical constituents as the active comparator except for ketoprofen
|
Active Comparator: Active
Topical ketoprofen 10% Cream
|
100 mg (10%) in 1 gram of topical cream applied three times per day for 7 days.
Safety follow up on day 14.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in mean pain intensity (100 mm VAS) during daily activities over the past 24 hours at the Day 3 visit (Day 3 +1)
Time Frame: 3 days
|
3 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CPRA; Pain curves over time; Percent change from baseline
Time Frame: 7 days
|
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
October 8, 2010
First Submitted That Met QC Criteria
October 15, 2010
First Posted (Estimate)
October 18, 2010
Study Record Updates
Last Update Posted (Estimate)
September 5, 2012
Last Update Submitted That Met QC Criteria
September 4, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Wounds and Injuries
- Soft Tissue Injuries
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ketoprofen
Other Study ID Numbers
- TDLP-110-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sprain
-
Decathlon SEEFOR, FranceTerminatedAnkle Sprain 1St Degree | Ankle Sprain 2Nd Degree | Ankle Sprain 3Rd DegreeFrance
-
National Defense Medical Center, TaiwanTri-Service General HospitalRecruitingAnkle Sprain 2Nd Degree | Ankle Sprain 3Rd DegreeTaiwan
-
Instituto Mexicano del Seguro SocialCompletedAnkle Sprain | Ankle Sprain 1St Degree | Ankle Sprain 2Nd DegreeMexico
-
Université Catholique de LouvainCompletedAnkle Sprain 1St Degree | Ankle Sprain 2Nd DegreeBelgium
-
Hospital Universitario Infanta LeonorCompletedMild Ankle SprainSpain
-
University Hospital, GrenobleCompleted
-
Vanderbilt University Medical CenterRecruitingMusculoskeletal Injury | Ankle Sprain 1St Degree | Ankle Sprain 2Nd DegreeUnited States
-
Walter van der WeegenGelre Hospitals; Medinova ClinicsRecruitingAnkle Sprains | Talofibular; Sprain (Strain)Netherlands
-
University of VirginiaNational Athletic Training Association Research & Education FoundationUnknownLateral Ankle SprainUnited States
Clinical Trials on Ketoprofen 10% cream
-
Imprimis Pharmaceuticals, Inc.Cato ResearchCompletedKetoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue InjurySprain | Strain | Acute Soft Tissue InjuryUnited States
-
Valletta Health B.V.TerminatedAtopic DermatitisSpain
-
ViroXis CorporationTerminatedMolluscum ContagiosumUnited States
-
Imprimis Pharmaceuticals, Inc.WithdrawnAcute Pain (Flare) Associated With Osteoarthritis (OA) of the Knee
-
Santalis Pharmaceuticals, Inc.Derm Research, PLLC; ClinDatrix, Inc.; Texas Dermatology and Laser Specialists; Clinical Trials of Texas, Inc... and other collaboratorsCompletedEczema | Atopic DermatitisUnited States
-
Taipei Veterans General Hospital, TaiwanCompletedHepatocellular Carcinoma
-
The Catholic University of KoreaUnknownDrug-Related Side Effects and Adverse Reactions | Epidermal Growth FactorKorea, Republic of
-
The Catholic University of KoreaUnknownDrug-Related Side Effects and Adverse Reactions | Epidermal Growth FactorKorea, Republic of
-
Northwestern UniversityCompletedAcne VulgarisUnited States
-
University of ManitobaCompleted